Wenli Jiang1, Youlutuziayi Rixiati2, Bingqing Zhao3, Yongcheng Li4, Chuangang Tang5, Jun Liu6. 1. Department of Biochemistry and Molecular Biology, College of Basic Medical, Navy Medical University, Shanghai, China. 2. Department of Pathology, Soochow University Medical School, Suzhou, China. 3. Plastic and Aesthetic Department, Tianjin Third Central Hospital, Tianjin, China. 4. Department of Medical Oncology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China. 5. Department of Breast Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China. 6. Department of Orthopedic Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China.
Abstract
PURPOSE: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). The incidence, prevalence, and outcomes of these systemic malignancies with bone metastases were then analyzed. RESULTS: A total of 67,605 patients with bone metastases at cancer diagnosis were included. The highest rate of bone metastases was observed in patients with small-cell lung cancer at the time of alternative primary site cancer diagnosis. Among 226,816 cases with metastatic disease, cases with breast cancer (65.58%), and prostate cancer (89.60%) had a high incidence proportion (>10%) of identified bone metastases. Patients with additional bone metastases resulting from prostate cancer, breast cancer, and testis cancer presented the best survival time. CONCLUSIONS: Incidence and prognosis differ considerably among bone metastases with different primary malignancy sites. These results may encourage appropriate application of bone imaging.
PURPOSE: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). The incidence, prevalence, and outcomes of these systemic malignancies with bone metastases were then analyzed. RESULTS: A total of 67,605 patients with bone metastases at cancer diagnosis were included. The highest rate of bone metastases was observed in patients with small-cell lung cancer at the time of alternative primary site cancer diagnosis. Among 226,816 cases with metastatic disease, cases with breast cancer (65.58%), and prostate cancer (89.60%) had a high incidence proportion (>10%) of identified bone metastases. Patients with additional bone metastases resulting from prostate cancer, breast cancer, and testis cancer presented the best survival time. CONCLUSIONS: Incidence and prognosis differ considerably among bone metastases with different primary malignancy sites. These results may encourage appropriate application of bone imaging.
Entities:
Keywords:
SEER; bone metastases; incidence; survival
Authors: Muhammad Umar Jawad; Brad H Pollock; Barton L Wise; Lauren N Zeitlinger; Edmond F O' Donnell; Janai R Carr-Ascher; Amy Cizik; Betty Ferrell; Steven W Thorpe; R Lor Randall Journal: J Surg Oncol Date: 2021-12-10 Impact factor: 2.885
Authors: Tobias Greve; Nithin Manohar Rayudu; Michael Dieckmeyer; Christof Boehm; Stefan Ruschke; Egon Burian; Christopher Kloth; Jan S Kirschke; Dimitrios C Karampinos; Thomas Baum; Karupppasamy Subburaj; Nico Sollmann Journal: Front Endocrinol (Lausanne) Date: 2022-07-11 Impact factor: 6.055